OLAPARIX 150MG

Description

Olaparib – Targeted PARP Inhibitor for Cancer Treatment

Olaparib is a breakthrough targeted cancer therapy belonging to the class of PARP (Poly ADP-Ribose Polymerase) inhibitors. It is primarily used in the treatment of ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer associated with BRCA1/BRCA2 gene mutations. By blocking the PARP enzyme, Olaparib prevents cancer cells from repairing their DNA, leading to cell death and improved survival outcomes.

At Oncomed Pharmacy, we provide authentic Olaparib tablets from trusted manufacturers, ensuring patients receive high-quality and effective targeted therapy.

Key Features of Olaparib

• Indications:

o Advanced ovarian cancer (maintenance therapy after platinum-based chemotherapy)

o Breast cancer with BRCA mutations (HER2-negative)

o Pancreatic cancer in patients with germline BRCA mutations

o Metastatic castration-resistant prostate cancer (mCRPC) with HRR mutations

• Formulation: Oral tablets, commonly available in 100 mg and 150 mg strengths.
• Mechanism of Action: Inhibits PARP enzymes, blocking cancer cells from repairing damaged DNA, which leads to selective cancer cell death.
• Patient Benefit: Improves progression-free survival and offers a personalized treatment option for BRCA-mutated cancers.

Why Buy Olaparib from Oncomed Pharmacy?

• 100% genuine and quality-tested targeted therapy.
• Available in multiple tablet strengths for personalized dosing.
• Affordable prices with countrywide delivery.
• Trusted oncology pharmacy specializing in genetic and precision cancer therapies.

Uses of Olaparib

• Ovarian Cancer: Maintenance therapy and treatment for BRCA-mutated advanced ovarian cancer.
• Breast Cancer: Effective in HER2-negative, BRCA-mutated breast cancer.
• Pancreatic Cancer: Maintenance therapy in patients with BRCA gene mutations.

• Prostate Cancer: Used in advanced/metastatic prostate cancer with HRR mutations